Logo.jpg
Celsion Receives $1.85 Million from the Sale of its New Jersey State Net Operating Losses
11 mai 2021 08h00 HE | Celsion CORP
Non-Dilutive Funding Strengthens Balance Sheet, Extends Cash Runway Beyond 2024 Sale of an Additional $5.0 Million of State NOLs Expected in Future Years LAWRENCEVILLE, N.J., May 11, 2021 ...
Logo.jpg
Celsion Corporation to Hold First Quarter 2021 Financial Results and Business Update Conference Call on Friday, May 14, 2021
07 mai 2021 08h30 HE | Celsion CORP
LAWRENCEVILLE, N.J., May 07, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines,...
Logo.jpg
Celsion Management Participates in Alliance Global Partners Virtual Series
22 avr. 2021 08h30 HE | Celsion CORP
LAWRENCEVILLE, N.J., April 22, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced...
Logo.jpg
Poster on Celsion Corporation’s Phase I/II OVATION 2 Study Presented at the Society of Gynecologic Oncology Virtual Annual Meeting on Women’s Cancer
01 avr. 2021 08h30 HE | Celsion CORP
Company reports further strengthening of R0 resection results in patients treated with GEN-1 LAWRENCEVILLE, N.J., April 01, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a...
Logo.jpg
Celsion Corporation to Hold Year-End 2020 Financial Results and Business Update Conference Call on Friday, March 19, 2021
12 mars 2021 08h45 HE | Celsion CORP
LAWRENCEVILLE, N.J., March 12, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines,...
Logo.jpg
Poster on Celsion Corporation’s Phase I/II OVATION 2 Study to be Presented at the Society of Gynecologic Oncology Virtual Annual Meeting on Women’s Cancer
02 mars 2021 08h45 HE | Celsion CORP
LAWRENCEVILLE, N.J., March 02, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines,...
Logo.jpg
Celsion Corporation Provides Clinical Update on Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer Including Encouraging Interim Resection Scores
25 févr. 2021 08h45 HE | Celsion CORP
Of 27 patients who completed interval debulking surgery, 80% of those treated with GEN-1 had an R0 resection compared with 58% of control patients, a 38% improvement To date 34 patients, or...
Logo.jpg
Celsion Announces Publication of Research on Fluorescence Imaging of ThermoDox® Uptake in International Journal of Hyperthermia
14 nov. 2019 08h00 HE | Celsion CORP
Independent Analysis Confirms Increasing Heating Time + ThermoDox® Improves Tumor Uptake of Drug, which may be visualized by real-time fluorescence imaging Study Confirms that ThermoDox® Can Deliver...
Logo.jpg
Celsion Corporation Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
03 oct. 2018 17h15 HE | Celsion CORP
LAWRENCEVILLE, N.J., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that on September 28, 2018, the Compensation...
Logo.jpg
Celsion Appoints Marianne Lambertson as Vice President of Communications and Investor Relations
17 sept. 2018 08h30 HE | Celsion CORP
  Lambertson brings executive experience to the newly created position,  reinforcing Celsion’s commitment to its strategic communications and investor relations objectives ...